Acasti Pharma (NASDAQ:ACST) and Matinas BioPharma Holdings (NYSEMKT:MTNB) are jumping after hours following Amarin’s FDA panel win to expand the label for its heart drug Vascepa.
ACST is up 12.3% and and MTNB is up 12.2% in postmarket trading.
The two are similar-sized peers to Amarin in the space.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.